290 related articles for article (PubMed ID: 25155604)
21. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
23. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
24. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
[TBL] [Abstract][Full Text] [Related]
26. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
[TBL] [Abstract][Full Text] [Related]
27. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
28. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
[TBL] [Abstract][Full Text] [Related]
29. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
30. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
van der Lee MJ; Blenke AA; Rongen GA; Verwey-van Wissen CP; Koopmans PP; Pharo C; Burger DM
Antimicrob Agents Chemother; 2007 Nov; 51(11):4098-104. PubMed ID: 17846135
[TBL] [Abstract][Full Text] [Related]
31. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Wire MB; Ballow C; Preston SL; Hendrix CW; Piliero PJ; Lou Y; Stein DS
AIDS; 2004 Apr; 18(6):897-907. PubMed ID: 15060437
[TBL] [Abstract][Full Text] [Related]
35. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
36. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
38. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
[TBL] [Abstract][Full Text] [Related]
39. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
DeJesus E; Piliero PJ; Summers K; Wire MB; Stein DS; Masterman A; Lou Y; Min SS; Shelton MJ
Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].
Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T
Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
